Sickle Cell Disease Trial, Recruiting (NCT06944067)

Sickle Cell Disease Trial, Recruiting NCT06944067 Sponsor: National Human Genome Research Institute (NHGRI) Condition: Sickle Cell Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06944067 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Sickle Cell Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People older than 2 years of age who have a confirmed diagnosis of Sickle Cell Disease (SCD), AND who meet at least one of the following conditions:
A history of more than ten transfusion episodes, or 20 or more transfusion units received (where this information is known)
A history of one or more blood antibody screening tests
A known specific genetic variant related to the condition (confirm with trial site)

Who may not be able to join:

People whose ability to make decisions is significantly impaired, even if a legal representative is available to assist
People who have previously received a transplant of any kind, such as an organ, bone marrow, or stem cell transplant
People who are currently taking medications that suppress the immune system at the time of joining the trial
People who are confirmed to be pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Neil A Hanchard, M.D., National Human Genome Research Institute (NHGRI)

Phone: (240) 328-0965

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06944067

Sponsor: National Human Genome Research Institute (NHGRI)

Phase: Not Applicable

Status: Recruiting

Condition: Sickle Cell Disease

Trial contact: (240) 328-0965

More information: https://clinicaltrials.gov/study/NCT06944067

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People older than 2 years of age who have a confirmed diagnosis of Sickle Cell Disease (SCD), AND who meet at least one of the following conditions:
A history of more than ten transfusion episodes, or 20 or more transfusion units received (where this information is known)
A history of one or more blood antibody screening tests
A known specific genetic variant related to the condition (confirm with trial site)

Who may not be able to join:

People whose ability to make decisions is significantly impaired, even if a legal representative is available to assist
People who have previously received a transplant of any kind, such as an organ, bone marrow, or stem cell transplant
People who are currently taking medications that suppress the immune system at the time of joining the trial
People who are confirmed to be pregnant

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

National Human Genome Research Institute (NHGRI)

Registry

ClinicalTrials.gov

Start date

24 June 2025

Est. completion

10 April 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Completion of analysis of previously identified risk loci to determine the relationship between genome structure and expression.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov